EmtinB(NeuroScientific Biopharmaceuticals)(EmtinB(NeuroScientific Biopharmaceuticals)) - 药物靶点：MT2_在研适应症：阿尔茨海默症，青光眼，肺纤维化_专利_临床

概要

基本信息

药物类型

合成多肽

别名-

靶点

MT2

作用机制

MT2调节剂(metallothionein 2A modulators)

治疗领域

神经系统疾病眼部疾病呼吸系统疾病+ [2]

在研适应症

阿尔茨海默症青光眼肺纤维化+ [2]

非在研适应症-

原研机构

Neuroscientific Biopharmaceuticals Ltd.

在研机构

Neuroscientific Biopharmaceuticals Ltd.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 EmtinB(NeuroScientific Biopharmaceuticals) 相关的临床试验

ACTRN12622001025729 / Withdrawn临床1期

A Phase 1, Single-Arm, Exploratory Open-Label Study Investigating Safety, Tolerability, and Pharmacokinetics of Subcutaneously Administered EmtinB in Healthy Adult Volunteers

开始日期2024-01-23

申办/合作机构

Neuroscientific Biopharmaceuticals Ltd.

ACTRN12622001019796 / Withdrawn临床1期

A Phase 1, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study Investigating Safety and Tolerability and Pharmacokinetics of Subcutaneously Administered EmtinB in Healthy Adult Volunteers

开始日期2023-09-07

申办/合作机构

Neuroscientific Biopharmaceuticals Ltd.

100 项与 EmtinB(NeuroScientific Biopharmaceuticals) 相关的临床结果

登录后查看更多信息

100 项与 EmtinB(NeuroScientific Biopharmaceuticals) 相关的转化医学

登录后查看更多信息

100 项与 EmtinB(NeuroScientific Biopharmaceuticals) 相关的专利（医药）

登录后查看更多信息

3

项与 EmtinB(NeuroScientific Biopharmaceuticals) 相关的文献（医药）

2010-04-01·Journal of Neuroscience Research3区 · 医学

A metallothionein mimetic peptide protects neurons against kainic acid‐induced excitotoxicity

3区 · 医学

Article

作者: Irina Korshunova ; Stanislava Pankratova ; Darya Kiryushko ; Alexander Zharkovsky ; Katrin Sonn ; Vladimir Berezin ; Elisabeth Bock

AbstractMetallothioneins I and II (MTI/II) are metal‐binding proteins overexpressed in response to brain injury. Recently, we have designed a peptide, termed EmtinB, which is modeled after the β‐domain of MT‐II and mimics the biological effects of MTI/II in vitro. Here, we demonstrate the neuroprotective effect of EmtinB in the in vitro and in vivo models of kainic acid (KA)‐induced neurotoxicity. We show that EmtinB passes the blood–brain barrier and is detectable in plasma for up to 24 hr. Treatment with EmtinB significantly attenuates seizures in C57BL/6J mice exposed to moderate (20 mg/kg) and high (30 mg/kg) KA doses and tends to decrease mortality induced by the high KA dose. Histopathological evaluation of hippocampal (CA3 and CA1) and cortical areas of mice treated with 20 mg/kg KA shows that EmtinB treatment reduces KA‐induced neurodegeneration in the CA1 region. These findings establish EmtinB as a promising target for therapeutic development. © 2009 Wiley‐Liss, Inc.

2009-08-01·European Journal of Cell Biology3区 · 生物学

Peptides modeled after the α-domain of metallothionein induce neurite outgrowth and promote survival of cerebellar granule neurons

3区 · 生物学

Article

作者: Vladimir Berezin ; Elisabeth Bock ; Malene Ambjørn ; Johanne Wirenfeldt Asmussen

Metallothionein (MT) is a metal-binding protein capable of preventing oxidative stress and apoptotic cell death in the central nervous system of mammals, and hence is of putative therapeutic value in the treatment of neurodegenerative disorders. Recently, we demonstrated that a peptide modeled after the beta-domain of MT, EmtinB, induced neurite outgrowth and increased neuronal survival through binding to receptors of the low-density lipoprotein receptor family (LDLR). The present study identified two MT alpha-domain-derived peptide sequences termed EmtinAn and EmtinAc, each consisting of 14 amino acids, as potent stimulators of neuronal differentiation and survival of primary neurons. In addition, we show that a peptide derived from the N-terminus of the MT beta-domain, EmtinBn, promotes neuronal survival. The neuritogenic and survival promoting effects of EmtinAc, similar to MT and EmtinB but not EmtinAn, were dependent on the functional integrity of LDLR. Moreover, EmtinAn and EmtinAc induced activation of extracellular signal-regulated kinase (ERK) and protein kinase B (PKB/Akt). We suggest that multiple functional sites of MT serve to cross-link MT receptor(s), thereby transducing signals leading to an increase in neurite outgrowth and survival.

2008-01-01·Journal of Neurochemistry

Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low‐density lipoprotein receptor family

Article

作者: Johanne W. Asmussen ; Elisabeth Bock ; Vladimir Berezin ; Malene Ambjørn ; Kamil Gotfryd ; Mats Lindstam ; Milena Penkowa ; Vladislav V. Kiselyov ; Søren K. Moestrup ; Christian Jacobsen

AbstractAccumulating evidence suggests that metallothionein (MT)‐I and ‐II promote neuronal survival and regeneration in vivo. The present study investigated the molecular mechanisms underlying the differentiation and survival‐promoting effects of MT and a peptide modeled after MT, EmtinB. Both MT and EmtinB directly stimulated neurite outgrowth and promoted survival in vitro using primary cultures of cerebellar granule neurons. In addition, expression and surface localization of megalin, a known MT receptor, and the related lipoprotein receptor‐related protein‐1 (LRP) are demonstrated in cerebellar granule neurons. By means of surface plasmon resonance MT and EmtinB were found to bind to both megalin and LRP. The bindings were abrogated in the presence of receptor‐associated protein‐1, an antagonist of the low‐density lipoprotein receptor family, which also inhibited MT‐ and EmtinB‐induced neurite outgrowth and survival. MT‐mediated neurite outgrowth was furthermore inhibited by an anti‐megalin serum. EmtinB‐mediated inhibition of apoptosis occurred without a reduction of caspase‐3 activity, but was associated with reduced expression of the pro‐apoptotic B‐cell leukemia/lymphoma‐2 interacting member of cell death (BimS). Finally, evidence is provided that MT and EmtinB activate extracellular signal‐regulated kinase, protein kinase B, and cAMP response element binding protein. Altogether, these results strongly suggest that MT and EmtinB induce their neuronal effects through direct binding to surface receptors belonging to the low‐density lipoprotein receptor family, such as megalin and LRP, thereby activating signal transduction pathways resulting in neurite outgrowth and survival.

100 项与 EmtinB(NeuroScientific Biopharmaceuticals) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床前	澳大利亚	Neuroscientific Biopharmaceuticals Ltd.	2022-01-30
青光眼	临床前	澳大利亚	Neuroscientific Biopharmaceuticals Ltd.	2022-01-30
肺纤维化	临床前	澳大利亚	Neuroscientific Biopharmaceuticals Ltd.	2022-01-30
多发性硬化症	药物发现	澳大利亚	Neuroscientific Biopharmaceuticals Ltd.	2022-01-30
视神经萎缩	药物发现	澳大利亚	Neuroscientific Biopharmaceuticals Ltd.	2022-01-30